Graph AI Raises $3 Mn To Automate Drug Safety Monitoring for Pharma Firms

SUMMARY

Pharmaceutical-sector focussed AI startup Graph AI’s $3 Mn seed funding round was led by Bessemer Venture Partners

The startup will use the capital for product innovation, team expansion, and fast-tracking market adoption for its pharmacovigilance automation platform

Graph AI provides an AI-native platform ‘Graph Safety’, which automates adverse drug event monitoring, regulatory submissions, and aggregates safety intelligence

Pharmaceutical-sector focussed AI startup Graph AI has secured $3 Mn (around INR 26.37 Cr) in its seed funding round led by Bessemer Venture Partners.

In a statement, the startup said it will use the funds for product innovation, team expansion, and fast-tracking market adoption for its proprietary pharmacovigilance automation platform.

Founded last year by Raghav Parvataraju (CEO), Vijay Ponukumati (CTO), Mohan Konyala (CPO), and Ashutosh Bordekar (CFO), Graph AI provides an AI-native platform ‘Graph Safety’, which automates adverse drug event (ADE) monitoring, regulatory submissions, and aggregates safety intelligence for the pharmaceutical and biotech industries.

Pharmacovigilance, which is mandated by global drug regulatory authorities, requires pharmaceutical companies to continuously monitor, detect, and report ADE across a drug’s entire lifecycle, from clinical trials to post-market use.

However, this $8 Bn market is fragmented and labour intensive, with companies generally relying on service firms to manually extract and process data from a wide range of unstructured sources, call centre transcripts, legal filings, medical literature, emails, and social media posts.

Graph AI claims Graph Safety fixes this problem through its “context-aware” AI. Graph AI said its platform is being used by enterprises and it has built a pipeline of over 7,000 marketed drugs. It claims that its clients have reported 70% efficiency gains and 90% faster reporting by using its platform.

The funding round comes as AI-powered solutions are reshaping the drug safety and compliance landscape. Healthtech innovators are also using AI for chatbots, telemedicine platforms, and wearable data analysis to enhance accessibility and real-time monitoring, bridging critical gaps in the healthcare landscape.

These startups are seeing strong interest from investors. For instance, AI-driven healthcare platform Reveal Healthtech raised $7.2 Mn in its Series A funding round last month. The startup provides specialised engineering, clinical model, and strategy support to healthcare organisations.